AR102120A1 - MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY - Google Patents
MODIFIED INTERFER WITH REDUCED IMMUNOGENICITYInfo
- Publication number
- AR102120A1 AR102120A1 ARP150103131A ARP150103131A AR102120A1 AR 102120 A1 AR102120 A1 AR 102120A1 AR P150103131 A ARP150103131 A AR P150103131A AR P150103131 A ARP150103131 A AR P150103131A AR 102120 A1 AR102120 A1 AR 102120A1
- Authority
- AR
- Argentina
- Prior art keywords
- modified
- reduced immunogenicity
- interfer
- nucleic acid
- acid molecule
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente describe un interferón modificado con inmunogenicidad reducida que comprende la sustitución de al menos 3 aminoácidos. Además, se describe una molécula de ácido nucleico que codifica para dicho interferón; una célula de expresión de proteínas recombinantes que comprende dicha molécula de ácido nucleico que codifica para dicho interferón modificado; donde dicha célula de expresión de proteínas recombinantes comprende un plásmido o vector que contiene dicha molécula de ácido nucleico.The present discloses a modified interferon with reduced immunogenicity comprising the substitution of at least 3 amino acids. In addition, a nucleic acid molecule encoding said interferon is described; a recombinant protein expression cell comprising said nucleic acid molecule encoding said modified interferon; wherein said recombinant protein expression cell comprises a plasmid or vector containing said nucleic acid molecule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP150103131A AR102120A1 (en) | 2015-09-29 | 2015-09-29 | MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP150103131A AR102120A1 (en) | 2015-09-29 | 2015-09-29 | MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY |
Publications (1)
Publication Number | Publication Date |
---|---|
AR102120A1 true AR102120A1 (en) | 2017-02-08 |
Family
ID=58698541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150103131A AR102120A1 (en) | 2015-09-29 | 2015-09-29 | MODIFIED INTERFER WITH REDUCED IMMUNOGENICITY |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR102120A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4076504A4 (en) * | 2019-12-17 | 2024-04-10 | Epivax Inc | Modified interferon-alpha-2 having reduced immunogenicity |
-
2015
- 2015-09-29 AR ARP150103131A patent/AR102120A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4076504A4 (en) * | 2019-12-17 | 2024-04-10 | Epivax Inc | Modified interferon-alpha-2 having reduced immunogenicity |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
AU2017335890B2 (en) | RNA-guided nucleic acid modifying enzymes and methods of use thereof | |
PH12018501355A1 (en) | Rsv f protein mutants | |
CL2018002825A1 (en) | Vrs vaccine | |
BR112017019625A2 (en) | udp-glycosyltransferases | |
MX2022008508A (en) | Enzymes and applications thereof. | |
BR112016007868A2 (en) | epstein-barr virus vaccines | |
BR112018008766A2 (en) | variants, compositions and methods and uses of the reduced factor viii cpg for the treatment of hemostasis disorders | |
TN2015000085A1 (en) | Fc containing polypeptides with altered glycosylation and reduced effector function | |
BR112014019901A8 (en) | RECOMBINANT FACTOR VIII PROTEINS | |
WO2016107818A8 (en) | Compositions and methods for protein glycosylation | |
CL2013001124A1 (en) | Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process. | |
ES2721309T3 (en) | Composition for preparing tagatose and method for preparing tagatose from fructose | |
BR112016015187A2 (en) | A method of inhibiting angiogenesis, or the growth of fusion proteins and their use | |
EA201401211A1 (en) | IMPROVED CHIMOZIN ENZYME OPTIONS | |
BR112017020308A2 (en) | udp-glycosyltransferases | |
NZ629843A (en) | Identification of channelrhodopsin-2 (chop2) mutations and methods of use | |
WO2016130628A8 (en) | Griffithsin mutants | |
CL2018000164A1 (en) | Recombinant vector of the orf virus. | |
CL2017000200A1 (en) | Enhanced host cell to produce proteins | |
PH12017502323A1 (en) | Novel xylanase | |
BR112016026842A2 (en) | preparation comprising factor viii and von willebrand factor peptides | |
AR102950A1 (en) | LIPASE AND POLINUCLEOTIDE VARIANTS CODING THEM | |
CO2017011431A2 (en) | Variant epidermal growth factor receptor fusion proteins iii - mesothelin | |
BR112021012240A2 (en) | Hematopoietic stem cell gene therapy for wiskott-aldrich syndrome |